Top-News

Melinta Therapeutics News

Keine aktuellen Kursdaten verfügbar
WKN: A2PEQ9
ISIN: US58549G2093
US-Symbol: MLNTQ
Typ: Aktie

Melinta Therapeutics News

01.10.19 - PR Newswire
Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2019
Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2019 52 Presentations by Coalition Members During the Annual Meeting PR Newswire
01.07.19 - PR Newswire
X-Biotix Therapeutics Joins Antimicrobials Working Group
X-Biotix Therapeutics Joins Antimicrobials Working Group PR Newswire
20.06.19 - PR Newswire
Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2019
Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2019 64 Presentations by Coalition Members During the Annual Meeting PR Newswire
20.06.19 - PR Newswire
Thinking about buying stock in Beyond Meat, DGSE, Interpace Diagnostics, Melinta Therapeutics, or Oracle?
Thinking about buying stock in Beyond Meat, DGSE, Interpace Diagnostics, Melinta Therapeutics, or Oracle? PR Newswire
07.06.19 - PR Newswire
Antimicrobials Working Group Commends Senator Isakson and Senator Casey for Introducing Legislation to Improve Access to Innovative Therapies to Fight Drug-Resistant Infections
Antimicrobials Working Group Commends Senator Isakson and Senator Casey for Introducing Legislation to Improve Access to Innovative Therapies to Fight Drug-​Resistant ...
12.04.19 - PR Newswire
Antimicrobials Working Group Highlights Member Company Participation at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
Antimicrobials Working Group Highlights Member Company Participation at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 78 ...
17.01.19 - PR Newswire
Antimicrobials Working Group Announces Updates to Leadership Team
Antimicrobials Working Group Announces Updates to Leadership Team PR Newswire
03.10.18 - PR Newswire
Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2018
Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2018 48 Presentations by Coalition Members During the Annual Meeting PR Newswire
06.06.18 - PR Newswire
Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2018
Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2018 88 Presentations by Coalition Members During the Annual Meeting PR Newswire
20.04.18 - PR Newswire
Antimicrobials Working Group Highlights Member Company Participation at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
Antimicrobials Working Group Highlights Member Company Participation at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 71 Abstracts to ...
29.11.17 - PR Newswire
Deerfield Supports Melinta Therapeutics Acquisition of The Medicines Company's Infectious Disease Business with a $240 million Commitment to Melinta and a $100 million Commitment to The Medicines Comp
Deerfield Supports Melinta Therapeutics Acquisition of The Medicines Company's Infectious Disease Business with a $240 million Commitment to Melinta and a $100 million ...
10.09.17 - PR Newswire
SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Cempra, Inc. -- CEMP
SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Cempra, Inc. -- CEMP PR Newswire
23.12.16 - PR Newswire
CEMP INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Shareholders of Commencement of a Class Action Involving Cempra, Inc. and a Lead Plaintiff Deadline of January 3, 2017
CEMP INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Shareholders of Commencement of a Class Action Involving Cempra, Inc. and a Lead Plaintiff Deadline of ...
14.12.16 - PR Newswire
CEMPRA INC. INVESTOR REMINDER: Hagens Berman Reminds Cempra Investors of Lead Plaintiff Deadline
CEMPRA INC. INVESTOR REMINDER: Hagens Berman Reminds Cempra Investors of Lead Plaintiff Deadline PR Newswire
01.12.16 - PR Newswire
Lifshitz & Miller Law Firm Announces Investigation of Adeptus Health Inc., Avid Technology, Inc., Cempra, Inc., Clovis Oncology, Inc., Impax Laboratories, Inc., Ligand Pharmaceuticals Incorporated
Lifshitz & Miller Law Firm Announces Investigation of Adeptus Health Inc., Avid Technology, Inc., Cempra, Inc., Clovis Oncology, Inc., Impax Laboratories, Inc., Ligand ...
30.11.16 - PR Newswire
Rosen Law Firm Reminds Cempra, Inc. Investors of Important Deadline in Class Action - CEMP
Rosen Law Firm Reminds Cempra, Inc. Investors of Important Deadline in Class Action - CEMP PR Newswire
28.11.16 - PR Newswire
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Cempra, Inc. To Contact The Firm Before Lead Plaintiff Deadline
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Cempra, Inc. To Contact The Firm Before Lead ...
22.11.16 - PR Newswire
Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against Cempra, Inc.
Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against Cempra, Inc. PR Newswire
16.11.16 - PR Newswire
CEMPRA (CEMP) SHAREHOLDER ALERT: Johnson & Weaver, LLP Announces Filing of Class Action Complaint Against Cempra, Inc.; Encourages all Investors to Contact the Firm for Information
CEMPRA (CEMP) SHAREHOLDER ALERT: Johnson & Weaver, LLP Announces Filing of Class Action Complaint Against Cempra, Inc.; Encourages all Investors to Contact the Firm ...
11.11.16 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cempra, Inc. of Class Action Lawsuit and Upcoming Deadline - CEMP
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cempra, Inc. of Class Action Lawsuit and Upcoming Deadline - CEMP PR ...

Newssuche

Videos

08:50 Uhr
Technical Trading: AUD/USD mit Mega Chance
AUD/USD Long Typ: Turbo Open End WKN: UM0EHU Hebel: 6,42 Laufzeit: OpenEnd Einstieg: Market ... Mehr »